The pharmaceutical companies behind Ozempic, Wegovy and other weight-loss meds push to prevent compounding pharmacies from making cheaper copies. They argue they can keep up with demand on their own.

The drug companies behind blockbuster weight loss and diabetes treatments have signaled that supply problems could soon be over, but many patients still have trouble getting the medicines. 

Several new studies find promising evidence that the GLP-1 class of drugs may have a cancer-preventive effect, especially for cancers linked to obesity.

Cheaper versions of Wegovy and Zepbound touted on social media could be fleeting. Copies are legal now because the brand-name drugs are in short supply. But the drugmakers are boosting production.

As more people try weight-loss drugs like Wegovy, some skip the brand name and buy compounded semaglutide from online pharmacies. But some of these may not follow state and federal standards.

New medications like Wegovy are changing the way people lose weight and manage obesity, but many Medicaid beneficiaries can't get them.

This change follows the recent FDA approval of the weight-loss drug for preventing heart attack and stroke in people with overweight or obesity.

The popular weight-loss drug can now be used to reduce the risk of stroke, heart attacks and other serious cardiovascular problems in patients who are overweight or who have obesity, the FDA said.

The announcement comes amid falling profits for the company. WeightWatchers has been facing declining stock prices since November as weight loss drugs, known as GLP1s, have soared in popularity.

WeightWatchers CEO Sima Sistani says the old advice around losing weight through determination and resilience and willpower was wrong: "The truth is that this is a chronic condition."

Weight-loss medications tamp down hunger — often dramatically — causing some people to lose the pleasure of communing over food at a festive family meal.

Eli Lilly said the obesity medicine, which helped adults in clinical studies lose about 20% of their body weight, will be available in the U.S. by the end of the year. The list price will be $1,060.

Popular weight-loss drugs mimic GLP-1, a hormone the body makes naturally after eating. Turns out some foods trigger GLP-1 better than others, making us feel full and eat less.

People taking weight-loss drugs Ozempic and Wegovy report a dampening of the urge to drink. Here's how the drugs curb cravings and what that could mean for helping treat addiction.

Drugmaker Novo Nordisk focuses on Black lawmakers and opinion leaders to spread the message that obesity is a chronic disease — worth treating at a cost of $1,000 or more a month.